| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Population Surveillance | 46 | 2016 | 2601 | 3.950 |
Why?
|
| Product Surveillance, Postmarketing | 23 | 2021 | 463 | 3.720 |
Why?
|
| Surgical Wound Infection | 44 | 2023 | 1544 | 3.560 |
Why?
|
| Cross Infection | 49 | 2024 | 1425 | 3.550 |
Why?
|
| Health Maintenance Organizations | 48 | 2013 | 658 | 3.030 |
Why?
|
| Staphylococcal Infections | 32 | 2023 | 1412 | 2.840 |
Why?
|
| Public Health Informatics | 12 | 2014 | 109 | 2.550 |
Why?
|
| Medical Records Systems, Computerized | 27 | 2014 | 1193 | 2.270 |
Why?
|
| Disease Outbreaks | 23 | 2024 | 1764 | 2.240 |
Why?
|
| Infection Control | 23 | 2024 | 985 | 2.000 |
Why?
|
| Computer Communication Networks | 7 | 2018 | 295 | 1.950 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 20 | 2023 | 704 | 1.890 |
Why?
|
| Sentinel Surveillance | 15 | 2016 | 292 | 1.800 |
Why?
|
| Bioterrorism | 9 | 2006 | 144 | 1.660 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 12 | 2018 | 495 | 1.630 |
Why?
|
| Chlorhexidine | 9 | 2023 | 160 | 1.520 |
Why?
|
| Electronic Health Records | 25 | 2024 | 4877 | 1.430 |
Why?
|
| Mupirocin | 7 | 2023 | 55 | 1.390 |
Why?
|
| United States Food and Drug Administration | 18 | 2022 | 1669 | 1.370 |
Why?
|
| Comparative Effectiveness Research | 8 | 2020 | 712 | 1.310 |
Why?
|
| Methicillin Resistance | 8 | 2011 | 198 | 1.290 |
Why?
|
| Carrier State | 14 | 2019 | 529 | 1.290 |
Why?
|
| Baths | 5 | 2023 | 53 | 1.210 |
Why?
|
| Delivery of Health Care | 16 | 2022 | 5367 | 1.190 |
Why?
|
| Pneumonia, Ventilator-Associated | 8 | 2022 | 280 | 1.160 |
Why?
|
| Databases, Factual | 25 | 2021 | 8081 | 1.160 |
Why?
|
| Anti-Bacterial Agents | 34 | 2024 | 7471 | 1.150 |
Why?
|
| Biomedical Research | 10 | 2021 | 3463 | 1.110 |
Why?
|
| Information Dissemination | 6 | 2020 | 1138 | 1.080 |
Why?
|
| Research Design | 15 | 2023 | 6217 | 1.070 |
Why?
|
| Coronary Artery Bypass | 10 | 2017 | 2194 | 1.050 |
Why?
|
| Hospitals | 22 | 2023 | 3906 | 1.010 |
Why?
|
| United States | 127 | 2024 | 73121 | 0.990 |
Why?
|
| Bacteremia | 14 | 2022 | 985 | 0.980 |
Why?
|
| Antibiotic Prophylaxis | 8 | 2008 | 640 | 0.970 |
Why?
|
| Intensive Care Units | 25 | 2023 | 3805 | 0.970 |
Why?
|
| Patient Care | 3 | 2019 | 629 | 0.960 |
Why?
|
| Influenza, Human | 10 | 2015 | 1540 | 0.960 |
Why?
|
| Drug Prescriptions | 20 | 2021 | 1677 | 0.960 |
Why?
|
| Streptococcal Infections | 10 | 2013 | 619 | 0.950 |
Why?
|
| Drug Utilization Review | 7 | 2010 | 248 | 0.950 |
Why?
|
| Medicare | 14 | 2023 | 6881 | 0.950 |
Why?
|
| Insurance Claim Review | 10 | 2020 | 745 | 0.920 |
Why?
|
| Ambulatory Care | 15 | 2014 | 2780 | 0.910 |
Why?
|
| Iodophors | 1 | 2023 | 7 | 0.910 |
Why?
|
| Disease Notification | 11 | 2013 | 95 | 0.890 |
Why?
|
| Health Services Research | 5 | 2019 | 1815 | 0.890 |
Why?
|
| Staphylococcus aureus | 12 | 2023 | 1461 | 0.880 |
Why?
|
| Multicenter Studies as Topic | 5 | 2021 | 1727 | 0.880 |
Why?
|
| Abnormalities, Drug-Induced | 4 | 2010 | 341 | 0.860 |
Why?
|
| Informed Consent | 5 | 2020 | 1012 | 0.850 |
Why?
|
| Ethics Committees, Research | 2 | 2014 | 196 | 0.830 |
Why?
|
| Guillain-Barre Syndrome | 4 | 2013 | 128 | 0.820 |
Why?
|
| Humans | 380 | 2024 | 768451 | 0.820 |
Why?
|
| Urinary Tract Infections | 14 | 2024 | 806 | 0.800 |
Why?
|
| Sepsis | 19 | 2023 | 2602 | 0.790 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2024 | 10358 | 0.790 |
Why?
|
| Hypolipidemic Agents | 6 | 2008 | 609 | 0.780 |
Why?
|
| Algorithms | 25 | 2021 | 14158 | 0.770 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2023 | 584 | 0.750 |
Why?
|
| Drug Therapy | 6 | 2006 | 504 | 0.750 |
Why?
|
| Confidentiality | 7 | 2018 | 606 | 0.750 |
Why?
|
| Anti-Infective Agents | 5 | 2023 | 987 | 0.740 |
Why?
|
| Meningococcal Vaccines | 5 | 2012 | 96 | 0.740 |
Why?
|
| Ethical Relativism | 1 | 2020 | 5 | 0.730 |
Why?
|
| Epidemiologic Research Design | 3 | 2013 | 368 | 0.690 |
Why?
|
| Drug Monitoring | 6 | 2007 | 964 | 0.680 |
Why?
|
| Disinfection | 6 | 2019 | 207 | 0.670 |
Why?
|
| Insurance, Health | 13 | 2020 | 2513 | 0.650 |
Why?
|
| Adrenergic beta-Antagonists | 5 | 2010 | 1244 | 0.620 |
Why?
|
| Models, Statistical | 11 | 2011 | 5103 | 0.610 |
Why?
|
| Hospitalization | 27 | 2024 | 10845 | 0.600 |
Why?
|
| Public Health Administration | 3 | 2009 | 242 | 0.600 |
Why?
|
| Evidence-Based Practice | 3 | 2021 | 500 | 0.600 |
Why?
|
| Retrospective Studies | 88 | 2024 | 81834 | 0.580 |
Why?
|
| Influenza Vaccines | 8 | 2016 | 781 | 0.580 |
Why?
|
| Respiratory Tract Infections | 7 | 2008 | 1013 | 0.570 |
Why?
|
| Cohort Studies | 65 | 2021 | 41797 | 0.570 |
Why?
|
| Antihypertensive Agents | 7 | 2013 | 2028 | 0.570 |
Why?
|
| Enterococcus | 5 | 2011 | 159 | 0.570 |
Why?
|
| Vancomycin Resistance | 5 | 2011 | 125 | 0.560 |
Why?
|
| Aged | 112 | 2024 | 171520 | 0.560 |
Why?
|
| Female | 196 | 2024 | 396943 | 0.550 |
Why?
|
| Cluster Analysis | 13 | 2020 | 2731 | 0.550 |
Why?
|
| Creatinine | 3 | 2007 | 1915 | 0.540 |
Why?
|
| Churg-Strauss Syndrome | 3 | 2007 | 75 | 0.530 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 338 | 0.530 |
Why?
|
| Drug Utilization | 13 | 2019 | 1192 | 0.520 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2014 | 952 | 0.520 |
Why?
|
| Massachusetts | 29 | 2014 | 8908 | 0.520 |
Why?
|
| Anti-Infective Agents, Local | 6 | 2023 | 248 | 0.510 |
Why?
|
| Pharmacoepidemiology | 5 | 2013 | 352 | 0.510 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2019 | 3253 | 0.510 |
Why?
|
| Data Collection | 13 | 2021 | 3329 | 0.500 |
Why?
|
| Research Support as Topic | 5 | 2021 | 699 | 0.500 |
Why?
|
| Patient Discharge | 15 | 2011 | 3471 | 0.490 |
Why?
|
| Middle Aged | 125 | 2024 | 223418 | 0.490 |
Why?
|
| Patient Isolation | 2 | 2014 | 100 | 0.490 |
Why?
|
| Streptococcus agalactiae | 5 | 2005 | 338 | 0.480 |
Why?
|
| Male | 160 | 2024 | 364781 | 0.480 |
Why?
|
| Immunity, Maternally-Acquired | 2 | 2013 | 112 | 0.470 |
Why?
|
| Premedication | 8 | 1993 | 246 | 0.460 |
Why?
|
| Adult | 112 | 2024 | 223542 | 0.450 |
Why?
|
| Quality Indicators, Health Care | 3 | 2017 | 1813 | 0.450 |
Why?
|
| Antidepressive Agents | 5 | 2009 | 2913 | 0.450 |
Why?
|
| Clinical Trials as Topic | 11 | 2017 | 8051 | 0.440 |
Why?
|
| Information Systems | 4 | 2014 | 397 | 0.440 |
Why?
|
| Bacterial Infections | 8 | 2004 | 1397 | 0.440 |
Why?
|
| Colon | 5 | 2023 | 1804 | 0.430 |
Why?
|
| Aged, 80 and over | 45 | 2024 | 59680 | 0.420 |
Why?
|
| Benchmarking | 4 | 2014 | 1058 | 0.420 |
Why?
|
| Clinical Protocols | 1 | 2018 | 1444 | 0.410 |
Why?
|
| Education, Professional | 1 | 2013 | 53 | 0.410 |
Why?
|
| Potassium | 2 | 2007 | 1319 | 0.410 |
Why?
|
| National Institutes of Health (U.S.) | 4 | 2023 | 794 | 0.410 |
Why?
|
| Space-Time Clustering | 6 | 2011 | 45 | 0.400 |
Why?
|
| Human Experimentation | 1 | 2013 | 124 | 0.400 |
Why?
|
| Moral Obligations | 1 | 2013 | 91 | 0.400 |
Why?
|
| Herpes Zoster | 4 | 2024 | 253 | 0.390 |
Why?
|
| Gram-Positive Bacterial Infections | 4 | 2011 | 342 | 0.390 |
Why?
|
| Pharmacies | 3 | 2004 | 171 | 0.390 |
Why?
|
| Puerperal Infection | 5 | 2001 | 44 | 0.380 |
Why?
|
| Cooperative Behavior | 6 | 2017 | 1514 | 0.380 |
Why?
|
| Safety Management | 2 | 2008 | 764 | 0.380 |
Why?
|
| Epidemiologic Methods | 8 | 2014 | 1337 | 0.380 |
Why?
|
| Patient Compliance | 7 | 2008 | 2696 | 0.380 |
Why?
|
| Arthroplasty, Replacement, Hip | 4 | 2017 | 1418 | 0.370 |
Why?
|
| Anticoagulants | 5 | 2022 | 4840 | 0.370 |
Why?
|
| Editorial Policies | 1 | 2016 | 459 | 0.370 |
Why?
|
| Hyperkalemia | 3 | 2007 | 233 | 0.370 |
Why?
|
| Biosurveillance | 1 | 2011 | 16 | 0.370 |
Why?
|
| Pneumococcal Vaccines | 3 | 2005 | 414 | 0.370 |
Why?
|
| Amphotericin B | 2 | 2001 | 143 | 0.370 |
Why?
|
| Insurance Claim Reporting | 5 | 2013 | 166 | 0.360 |
Why?
|
| Rhabdomyolysis | 4 | 2007 | 152 | 0.360 |
Why?
|
| Communicable Diseases | 3 | 2009 | 875 | 0.360 |
Why?
|
| Research Subjects | 1 | 2013 | 249 | 0.360 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 4 | 2024 | 590 | 0.360 |
Why?
|
| Cephalosporins | 5 | 2001 | 200 | 0.360 |
Why?
|
| Clinical Pharmacy Information Systems | 5 | 2006 | 102 | 0.360 |
Why?
|
| Data Interpretation, Statistical | 7 | 2020 | 2705 | 0.350 |
Why?
|
| Catheters, Indwelling | 8 | 2003 | 436 | 0.350 |
Why?
|
| Anti-Asthmatic Agents | 4 | 2007 | 578 | 0.350 |
Why?
|
| Outpatients | 6 | 2008 | 1607 | 0.350 |
Why?
|
| Adolescent | 53 | 2019 | 89168 | 0.350 |
Why?
|
| Gout | 3 | 2024 | 621 | 0.350 |
Why?
|
| Logistic Models | 16 | 2017 | 13324 | 0.350 |
Why?
|
| Calcium Channel Blockers | 3 | 2021 | 692 | 0.350 |
Why?
|
| Catheter-Related Infections | 3 | 2022 | 275 | 0.350 |
Why?
|
| Environment, Controlled | 2 | 2007 | 42 | 0.350 |
Why?
|
| California | 11 | 2018 | 1444 | 0.340 |
Why?
|
| Patients' Rooms | 2 | 2008 | 62 | 0.340 |
Why?
|
| Risk | 20 | 2014 | 9642 | 0.340 |
Why?
|
| Infant, Newborn | 36 | 2015 | 26395 | 0.340 |
Why?
|
| Confidence Intervals | 8 | 2014 | 2932 | 0.340 |
Why?
|
| Antifungal Agents | 3 | 2013 | 761 | 0.330 |
Why?
|
| Cefazolin | 3 | 2001 | 95 | 0.330 |
Why?
|
| Hospital Information Systems | 4 | 2005 | 394 | 0.330 |
Why?
|
| Hypoglycemia | 2 | 2010 | 894 | 0.330 |
Why?
|
| Pneumococcal Infections | 3 | 2005 | 529 | 0.330 |
Why?
|
| Organizational Policy | 1 | 2012 | 434 | 0.330 |
Why?
|
| Pregnancy | 30 | 2020 | 30179 | 0.330 |
Why?
|
| Anthrax | 3 | 2008 | 83 | 0.320 |
Why?
|
| Incidence | 35 | 2024 | 21552 | 0.320 |
Why?
|
| Incretins | 2 | 2020 | 100 | 0.320 |
Why?
|
| Office Visits | 3 | 2009 | 596 | 0.320 |
Why?
|
| Mass Vaccination | 2 | 2012 | 110 | 0.320 |
Why?
|
| Publishing | 1 | 2016 | 836 | 0.310 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2013 | 1518 | 0.310 |
Why?
|
| Boston | 18 | 2015 | 9361 | 0.310 |
Why?
|
| Health Planning Guidelines | 1 | 2009 | 151 | 0.310 |
Why?
|
| Arthroplasty, Replacement, Knee | 4 | 2013 | 1401 | 0.310 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2009 | 80 | 0.310 |
Why?
|
| Hypoglycemic Agents | 7 | 2020 | 3111 | 0.310 |
Why?
|
| Quality Improvement | 4 | 2020 | 3858 | 0.310 |
Why?
|
| Databases as Topic | 5 | 2014 | 475 | 0.310 |
Why?
|
| Risk Factors | 50 | 2023 | 74915 | 0.310 |
Why?
|
| Disease Transmission, Infectious | 4 | 2019 | 562 | 0.310 |
Why?
|
| Drug Labeling | 3 | 2006 | 250 | 0.300 |
Why?
|
| Antibodies, Bacterial | 3 | 2013 | 1481 | 0.300 |
Why?
|
| Computer Security | 5 | 2014 | 260 | 0.300 |
Why?
|
| Health Services Misuse | 3 | 2020 | 249 | 0.300 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2008 | 429 | 0.300 |
Why?
|
| Managed Care Programs | 6 | 2005 | 941 | 0.300 |
Why?
|
| Treatment Refusal | 2 | 2001 | 432 | 0.300 |
Why?
|
| Monitoring, Physiologic | 4 | 2012 | 1795 | 0.290 |
Why?
|
| Software | 5 | 2014 | 4463 | 0.290 |
Why?
|
| Tartrates | 1 | 2007 | 13 | 0.290 |
Why?
|
| Drug Resistance, Microbial | 6 | 2014 | 830 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2020 | 12242 | 0.290 |
Why?
|
| Administration, Intranasal | 4 | 2023 | 485 | 0.290 |
Why?
|
| Pneumonia | 6 | 2024 | 2162 | 0.290 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2010 | 348 | 0.290 |
Why?
|
| Gram-Negative Bacteria | 4 | 2012 | 276 | 0.290 |
Why?
|
| Medical Records | 12 | 2014 | 1413 | 0.280 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2010 | 2538 | 0.280 |
Why?
|
| Child, Preschool | 35 | 2016 | 42623 | 0.280 |
Why?
|
| Atenolol | 1 | 2007 | 99 | 0.280 |
Why?
|
| Metoprolol | 1 | 2007 | 90 | 0.280 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 2544 | 0.280 |
Why?
|
| Propanolamines | 1 | 2007 | 164 | 0.270 |
Why?
|
| International Classification of Diseases | 10 | 2016 | 925 | 0.270 |
Why?
|
| Vaccines | 3 | 2015 | 845 | 0.270 |
Why?
|
| Amoxicillin | 4 | 2008 | 181 | 0.270 |
Why?
|
| Health Policy | 4 | 2021 | 2699 | 0.270 |
Why?
|
| Universal Precautions | 1 | 2006 | 34 | 0.270 |
Why?
|
| Therapeutics | 3 | 2021 | 113 | 0.270 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2019 | 2040 | 0.270 |
Why?
|
| Case-Control Studies | 20 | 2015 | 22293 | 0.270 |
Why?
|
| Attitude of Health Personnel | 3 | 2007 | 3922 | 0.270 |
Why?
|
| Infant | 32 | 2016 | 36497 | 0.270 |
Why?
|
| Drug Evaluation | 1 | 2007 | 642 | 0.260 |
Why?
|
| Automation | 3 | 2004 | 588 | 0.260 |
Why?
|
| Research | 2 | 2019 | 1984 | 0.260 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2011 | 614 | 0.260 |
Why?
|
| Asthma | 7 | 2007 | 6274 | 0.260 |
Why?
|
| Chickenpox | 2 | 1997 | 96 | 0.260 |
Why?
|
| Carbazoles | 1 | 2007 | 221 | 0.250 |
Why?
|
| Pregnancy Complications | 2 | 2011 | 2969 | 0.250 |
Why?
|
| Telephone | 1 | 2009 | 630 | 0.250 |
Why?
|
| Cardiovascular Diseases | 6 | 2020 | 15638 | 0.250 |
Why?
|
| Ethics, Research | 2 | 2019 | 177 | 0.250 |
Why?
|
| Clofibric Acid | 1 | 2004 | 8 | 0.250 |
Why?
|
| Air Microbiology | 1 | 2005 | 95 | 0.240 |
Why?
|
| Gram-Positive Bacteria | 2 | 2003 | 180 | 0.240 |
Why?
|
| Inappropriate Prescribing | 2 | 2024 | 212 | 0.240 |
Why?
|
| Diagnostic Tests, Routine | 4 | 2006 | 792 | 0.240 |
Why?
|
| Gout Suppressants | 2 | 2006 | 177 | 0.240 |
Why?
|
| Streptococcal Vaccines | 1 | 2005 | 46 | 0.240 |
Why?
|
| Systemic Inflammatory Response Syndrome | 3 | 2003 | 620 | 0.240 |
Why?
|
| Breast Feeding | 4 | 2009 | 1365 | 0.240 |
Why?
|
| Antitubercular Agents | 3 | 2004 | 1390 | 0.240 |
Why?
|
| Systems Integration | 1 | 2007 | 429 | 0.240 |
Why?
|
| Vancomycin | 4 | 2006 | 506 | 0.240 |
Why?
|
| Child | 42 | 2023 | 80863 | 0.240 |
Why?
|
| Amiodarone | 1 | 2006 | 217 | 0.240 |
Why?
|
| Attitude to Health | 3 | 2003 | 2030 | 0.240 |
Why?
|
| Models, Theoretical | 2 | 2008 | 3590 | 0.240 |
Why?
|
| Registries | 4 | 2016 | 8373 | 0.240 |
Why?
|
| Hepatitis B | 4 | 2008 | 707 | 0.240 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2002 | 1126 | 0.240 |
Why?
|
| Community-Acquired Infections | 2 | 2011 | 473 | 0.230 |
Why?
|
| Atrial Fibrillation | 5 | 2022 | 5162 | 0.230 |
Why?
|
| Allopurinol | 1 | 2006 | 198 | 0.230 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 3230 | 0.230 |
Why?
|
| Gastrointestinal Diseases | 4 | 2009 | 1207 | 0.230 |
Why?
|
| Neurotoxins | 2 | 2015 | 241 | 0.230 |
Why?
|
| Vaccination | 4 | 2013 | 3434 | 0.230 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2003 | 1359 | 0.230 |
Why?
|
| Hospitals, Community | 4 | 2024 | 365 | 0.230 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2024 | 49 | 0.220 |
Why?
|
| Reminder Systems | 2 | 2007 | 386 | 0.220 |
Why?
|
| Sensitivity and Specificity | 15 | 2015 | 14728 | 0.220 |
Why?
|
| Education, Medical, Continuing | 3 | 2007 | 829 | 0.220 |
Why?
|
| Minnesota | 4 | 2010 | 338 | 0.220 |
Why?
|
| Dementia | 3 | 2024 | 2723 | 0.220 |
Why?
|
| Personnel, Hospital | 4 | 2008 | 285 | 0.220 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2008 | 518 | 0.210 |
Why?
|
| Smallpox | 1 | 2003 | 43 | 0.210 |
Why?
|
| Odds Ratio | 13 | 2015 | 9687 | 0.210 |
Why?
|
| Spironolactone | 1 | 2007 | 412 | 0.210 |
Why?
|
| Evidence-Based Medicine | 4 | 2021 | 3708 | 0.210 |
Why?
|
| Blood-Borne Pathogens | 1 | 2003 | 52 | 0.210 |
Why?
|
| Health Education | 2 | 2008 | 1059 | 0.210 |
Why?
|
| Forecasting | 5 | 2019 | 2950 | 0.210 |
Why?
|
| Enterocolitis, Pseudomembranous | 3 | 2014 | 264 | 0.210 |
Why?
|
| Pediatrics | 5 | 2014 | 3622 | 0.210 |
Why?
|
| Smallpox Vaccine | 1 | 2003 | 77 | 0.210 |
Why?
|
| Computer Simulation | 4 | 2012 | 6278 | 0.210 |
Why?
|
| Multivariate Analysis | 8 | 2015 | 12096 | 0.200 |
Why?
|
| Disaster Planning | 2 | 2005 | 560 | 0.200 |
Why?
|
| Hyperlipidemias | 2 | 1999 | 773 | 0.200 |
Why?
|
| Guideline Adherence | 6 | 2012 | 2239 | 0.200 |
Why?
|
| Cation Exchange Resins | 2 | 1992 | 19 | 0.200 |
Why?
|
| Cesarean Section | 5 | 2004 | 1414 | 0.200 |
Why?
|
| Patient Selection | 4 | 2021 | 4266 | 0.200 |
Why?
|
| Sorbitol | 2 | 1992 | 60 | 0.200 |
Why?
|
| Time Factors | 25 | 2020 | 40271 | 0.200 |
Why?
|
| Duodenal Ulcer | 1 | 2002 | 121 | 0.200 |
Why?
|
| Medical Order Entry Systems | 2 | 2024 | 522 | 0.200 |
Why?
|
| Immunization Programs | 2 | 2012 | 267 | 0.200 |
Why?
|
| Stomach Ulcer | 1 | 2002 | 122 | 0.200 |
Why?
|
| Decision Making | 6 | 2021 | 3961 | 0.200 |
Why?
|
| Triage | 1 | 2009 | 997 | 0.200 |
Why?
|
| Seizures | 2 | 2015 | 2996 | 0.200 |
Why?
|
| Polystyrenes | 2 | 1992 | 105 | 0.190 |
Why?
|
| Gestational Age | 7 | 2015 | 3615 | 0.190 |
Why?
|
| Duodenal Diseases | 1 | 2002 | 101 | 0.190 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2003 | 193 | 0.190 |
Why?
|
| Hernia, Femoral | 2 | 1992 | 18 | 0.190 |
Why?
|
| Long QT Syndrome | 1 | 2006 | 472 | 0.190 |
Why?
|
| Cardiovascular Agents | 1 | 2008 | 849 | 0.190 |
Why?
|
| Pregnancy Complications, Infectious | 6 | 2014 | 2181 | 0.190 |
Why?
|
| Streptococcus pneumoniae | 2 | 2005 | 765 | 0.190 |
Why?
|
| Tuberculosis | 4 | 2010 | 2030 | 0.190 |
Why?
|
| Ambulatory Care Information Systems | 1 | 2001 | 89 | 0.190 |
Why?
|
| Pharmaceutical Preparations | 3 | 2022 | 1089 | 0.190 |
Why?
|
| Pharmaceutical Services | 1 | 2002 | 143 | 0.190 |
Why?
|
| Intraoperative Care | 2 | 2003 | 772 | 0.180 |
Why?
|
| Canada | 6 | 2019 | 2143 | 0.180 |
Why?
|
| Pilot Projects | 7 | 2016 | 8730 | 0.180 |
Why?
|
| Drug Design | 1 | 2006 | 1050 | 0.180 |
Why?
|
| Alendronate | 1 | 2002 | 174 | 0.180 |
Why?
|
| Weaning | 1 | 2001 | 103 | 0.180 |
Why?
|
| Random Allocation | 9 | 2011 | 2399 | 0.180 |
Why?
|
| Thiazolidinediones | 2 | 2020 | 462 | 0.180 |
Why?
|
| Quality of Health Care | 4 | 2010 | 4340 | 0.180 |
Why?
|
| Medical Informatics Applications | 1 | 2002 | 180 | 0.180 |
Why?
|
| Risk Assessment | 18 | 2022 | 24311 | 0.180 |
Why?
|
| Young Adult | 22 | 2019 | 60045 | 0.180 |
Why?
|
| Patient Education as Topic | 4 | 2024 | 2339 | 0.180 |
Why?
|
| Peptic Ulcer | 1 | 2002 | 222 | 0.180 |
Why?
|
| Neuralgia | 2 | 1997 | 620 | 0.180 |
Why?
|
| Antiviral Agents | 4 | 2021 | 3063 | 0.180 |
Why?
|
| Acute Kidney Injury | 4 | 2012 | 1943 | 0.180 |
Why?
|
| Operating Rooms | 1 | 2007 | 799 | 0.180 |
Why?
|
| Predictive Value of Tests | 13 | 2012 | 15460 | 0.170 |
Why?
|
| Age Factors | 17 | 2016 | 18478 | 0.170 |
Why?
|
| Depressive Disorder | 2 | 2007 | 3738 | 0.170 |
Why?
|
| Intestinal Perforation | 1 | 2002 | 253 | 0.170 |
Why?
|
| Patient Participation | 1 | 2009 | 1450 | 0.170 |
Why?
|
| Catheterization, Central Venous | 2 | 2003 | 530 | 0.170 |
Why?
|
| Cefaclor | 2 | 1990 | 8 | 0.170 |
Why?
|
| Health Personnel | 2 | 2016 | 3384 | 0.170 |
Why?
|
| Drugs, Generic | 2 | 2015 | 454 | 0.170 |
Why?
|
| Antiparkinson Agents | 1 | 2021 | 184 | 0.170 |
Why?
|
| Dopamine Antagonists | 1 | 2021 | 289 | 0.170 |
Why?
|
| Sample Size | 1 | 2023 | 851 | 0.170 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2004 | 846 | 0.170 |
Why?
|
| Cephalexin | 2 | 1990 | 37 | 0.170 |
Why?
|
| Thyroid Gland | 1 | 2006 | 1172 | 0.170 |
Why?
|
| Serum Sickness | 2 | 1990 | 27 | 0.170 |
Why?
|
| Congresses as Topic | 3 | 2020 | 810 | 0.170 |
Why?
|
| Anesthetics | 2 | 2015 | 525 | 0.170 |
Why?
|
| Academic Medical Centers | 7 | 2019 | 2785 | 0.170 |
Why?
|
| Rotavirus Vaccines | 2 | 2014 | 62 | 0.170 |
Why?
|
| Medicaid | 3 | 2023 | 2843 | 0.160 |
Why?
|
| Information Services | 1 | 2020 | 237 | 0.160 |
Why?
|
| Laparoscopy | 2 | 2022 | 2056 | 0.160 |
Why?
|
| Intussusception | 2 | 2014 | 117 | 0.160 |
Why?
|
| Limulus Test | 1 | 1998 | 19 | 0.160 |
Why?
|
| Patient Readmission | 4 | 2013 | 3308 | 0.160 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 1999 | 60 | 0.160 |
Why?
|
| Reproducibility of Results | 13 | 2015 | 20231 | 0.160 |
Why?
|
| Competitive Medical Plans | 2 | 2009 | 26 | 0.160 |
Why?
|
| Computer Systems | 3 | 2014 | 470 | 0.160 |
Why?
|
| Breast | 3 | 1993 | 1976 | 0.150 |
Why?
|
| Data Mining | 2 | 2014 | 561 | 0.150 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 450 | 0.150 |
Why?
|
| Patient Transfer | 5 | 2012 | 796 | 0.150 |
Why?
|
| Hernia, Inguinal | 2 | 1992 | 225 | 0.150 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2020 | 182 | 0.150 |
Why?
|
| Drug Interactions | 6 | 2006 | 1421 | 0.150 |
Why?
|
| Fever | 3 | 2005 | 1622 | 0.150 |
Why?
|
| Prospective Studies | 26 | 2024 | 54914 | 0.150 |
Why?
|
| Syndrome | 3 | 2010 | 3278 | 0.150 |
Why?
|
| Probability | 5 | 2008 | 2483 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2012 | 3440 | 0.150 |
Why?
|
| Puerperal Disorders | 1 | 2001 | 303 | 0.150 |
Why?
|
| Internet | 1 | 2010 | 3123 | 0.150 |
Why?
|
| Epidemiology | 2 | 2011 | 280 | 0.150 |
Why?
|
| Microbiological Techniques | 1 | 1998 | 97 | 0.150 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2003 | 1209 | 0.150 |
Why?
|
| Database Management Systems | 2 | 2011 | 256 | 0.150 |
Why?
|
| Thoracic Surgery | 1 | 2004 | 727 | 0.140 |
Why?
|
| Medical Audit | 4 | 2014 | 454 | 0.140 |
Why?
|
| Alzheimer Disease | 4 | 2024 | 8721 | 0.140 |
Why?
|
| Fungemia | 1 | 1997 | 57 | 0.140 |
Why?
|
| Disinfectants | 3 | 2014 | 129 | 0.140 |
Why?
|
| Gastroenteritis | 3 | 2012 | 236 | 0.140 |
Why?
|
| Thromboembolism | 2 | 2022 | 1006 | 0.140 |
Why?
|
| Hysterectomy | 2 | 2023 | 863 | 0.140 |
Why?
|
| Superinfection | 1 | 1997 | 63 | 0.140 |
Why?
|
| Postoperative Care | 2 | 2002 | 1481 | 0.140 |
Why?
|
| Respiration, Artificial | 3 | 2015 | 2723 | 0.140 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2010 | 583 | 0.140 |
Why?
|
| Sex Factors | 10 | 2016 | 10647 | 0.140 |
Why?
|
| Heart Failure | 3 | 2019 | 11857 | 0.140 |
Why?
|
| Skin Diseases, Bacterial | 1 | 1997 | 67 | 0.140 |
Why?
|
| Cefamandole | 3 | 1984 | 9 | 0.140 |
Why?
|
| Age Distribution | 5 | 2010 | 2881 | 0.140 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2016 | 1064 | 0.140 |
Why?
|
| Drug Administration Schedule | 5 | 2007 | 4861 | 0.140 |
Why?
|
| Urinary Catheterization | 5 | 1987 | 195 | 0.140 |
Why?
|
| Teratogens | 2 | 2008 | 117 | 0.140 |
Why?
|
| Clinical Coding | 2 | 2015 | 186 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2020 | 2254 | 0.140 |
Why?
|
| Primary Health Care | 5 | 2016 | 4737 | 0.130 |
Why?
|
| Postpartum Hemorrhage | 1 | 2020 | 273 | 0.130 |
Why?
|
| Public Health | 2 | 2012 | 2693 | 0.130 |
Why?
|
| Endometritis | 2 | 1993 | 49 | 0.130 |
Why?
|
| Hospitals, Teaching | 4 | 2006 | 1158 | 0.130 |
Why?
|
| Treatment Outcome | 12 | 2021 | 65409 | 0.130 |
Why?
|
| Multiple Organ Failure | 2 | 2015 | 387 | 0.130 |
Why?
|
| Ibuprofen | 1 | 1997 | 229 | 0.130 |
Why?
|
| Endotoxins | 1 | 1998 | 520 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 717 | 0.130 |
Why?
|
| Critical Care | 2 | 2008 | 2717 | 0.130 |
Why?
|
| Length of Stay | 13 | 2024 | 6521 | 0.130 |
Why?
|
| Hospital Costs | 5 | 2015 | 959 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 3734 | 0.130 |
Why?
|
| Epidemiologic Measurements | 2 | 2005 | 23 | 0.130 |
Why?
|
| Ownership | 1 | 2018 | 343 | 0.130 |
Why?
|
| Terfenadine | 1 | 1995 | 15 | 0.130 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2020 | 317 | 0.130 |
Why?
|
| Cephalothin | 3 | 1984 | 28 | 0.130 |
Why?
|
| Soft Tissue Infections | 1 | 1997 | 168 | 0.130 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 2 | 2006 | 91 | 0.120 |
Why?
|
| Access to Information | 1 | 2018 | 317 | 0.120 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 39430 | 0.120 |
Why?
|
| Pseudomonas Infections | 3 | 1984 | 623 | 0.120 |
Why?
|
| Inpatients | 4 | 2024 | 2561 | 0.120 |
Why?
|
| Patient-Centered Care | 3 | 2014 | 1439 | 0.120 |
Why?
|
| Ranitidine | 1 | 1994 | 34 | 0.120 |
Why?
|
| Regression Analysis | 9 | 2012 | 6353 | 0.120 |
Why?
|
| Histamine H1 Antagonists | 1 | 1995 | 101 | 0.120 |
Why?
|
| Fetal Mortality | 1 | 2014 | 19 | 0.120 |
Why?
|
| Cefonicid | 3 | 1990 | 7 | 0.120 |
Why?
|
| Hygiene | 2 | 2019 | 95 | 0.120 |
Why?
|
| Obstetrics | 2 | 2011 | 676 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 1995 | 144 | 0.110 |
Why?
|
| Hemorrhage | 3 | 2022 | 3458 | 0.110 |
Why?
|
| Colectomy | 1 | 2019 | 700 | 0.110 |
Why?
|
| Infant Mortality | 6 | 2001 | 756 | 0.110 |
Why?
|
| Meta-Analysis as Topic | 1 | 1999 | 1364 | 0.110 |
Why?
|
| Mediastinitis | 1 | 2013 | 49 | 0.110 |
Why?
|
| Diabetes Mellitus | 4 | 2012 | 5887 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2004 | 2119 | 0.110 |
Why?
|
| Bacteriuria | 4 | 2015 | 102 | 0.110 |
Why?
|
| Perinatal Mortality | 1 | 2014 | 102 | 0.110 |
Why?
|
| Computers, Handheld | 1 | 2016 | 211 | 0.110 |
Why?
|
| Poisson Distribution | 3 | 2005 | 509 | 0.110 |
Why?
|
| Pennsylvania | 2 | 2020 | 616 | 0.110 |
Why?
|
| Ventilator Weaning | 1 | 2015 | 170 | 0.110 |
Why?
|
| Cefoxitin | 1 | 1993 | 35 | 0.110 |
Why?
|
| Desensitization, Immunologic | 1 | 1999 | 563 | 0.110 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2015 | 464 | 0.110 |
Why?
|
| Program Development | 2 | 2012 | 1296 | 0.110 |
Why?
|
| Pelvic Inflammatory Disease | 2 | 2003 | 96 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 3 | 2006 | 2179 | 0.110 |
Why?
|
| Liver | 2 | 2006 | 7575 | 0.110 |
Why?
|
| Comorbidity | 9 | 2020 | 10601 | 0.110 |
Why?
|
| Drug Therapy, Combination | 4 | 2007 | 6320 | 0.110 |
Why?
|
| Ceftriaxone | 1 | 1994 | 175 | 0.110 |
Why?
|
| Hospital Shared Services | 1 | 2012 | 16 | 0.110 |
Why?
|
| Candidiasis | 1 | 2015 | 367 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 2279 | 0.100 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1994 | 147 | 0.100 |
Why?
|
| Vaccines, Conjugate | 2 | 2012 | 334 | 0.100 |
Why?
|
| Antibodies | 1 | 2001 | 2425 | 0.100 |
Why?
|
| Health Care Costs | 2 | 2003 | 3265 | 0.100 |
Why?
|
| Pharmaceutical Vehicles | 1 | 1992 | 57 | 0.100 |
Why?
|
| Pancreatitis | 1 | 2019 | 1087 | 0.100 |
Why?
|
| Bayes Theorem | 1 | 2001 | 2358 | 0.100 |
Why?
|
| Equipment and Supplies | 2 | 2012 | 273 | 0.100 |
Why?
|
| Fumarates | 1 | 2013 | 132 | 0.100 |
Why?
|
| Schools, Medical | 1 | 2019 | 881 | 0.100 |
Why?
|
| Prevalence | 9 | 2011 | 15880 | 0.100 |
Why?
|
| Histocompatibility Testing | 1 | 2014 | 716 | 0.100 |
Why?
|
| Intellectual Property | 1 | 2012 | 32 | 0.100 |
Why?
|
| Sex Distribution | 5 | 2003 | 2286 | 0.100 |
Why?
|
| Diabetes Complications | 4 | 2020 | 1322 | 0.100 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2015 | 1176 | 0.100 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2015 | 738 | 0.100 |
Why?
|
| Health Facility Administration | 1 | 2011 | 29 | 0.100 |
Why?
|
| Polypharmacy | 3 | 2024 | 307 | 0.100 |
Why?
|
| Fractures, Bone | 2 | 2003 | 2063 | 0.100 |
Why?
|
| Health Planning | 2 | 2014 | 233 | 0.100 |
Why?
|
| Vitamin A | 1 | 2015 | 611 | 0.100 |
Why?
|
| Carotenoids | 1 | 2015 | 621 | 0.100 |
Why?
|
| Models, Biological | 3 | 2005 | 9505 | 0.100 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 2863 | 0.100 |
Why?
|
| Risk Management | 1 | 2015 | 558 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2007 | 749 | 0.100 |
Why?
|
| Sulfamethoxazole | 2 | 2006 | 52 | 0.100 |
Why?
|
| Angioedema | 1 | 2013 | 184 | 0.090 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2013 | 298 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 21156 | 0.090 |
Why?
|
| Nasopharynx | 2 | 2005 | 420 | 0.090 |
Why?
|
| Hospitals, County | 1 | 2011 | 18 | 0.090 |
Why?
|
| Bupropion | 1 | 2013 | 304 | 0.090 |
Why?
|
| Quinoxalines | 1 | 2013 | 297 | 0.090 |
Why?
|
| Nicotinic Agonists | 1 | 2013 | 266 | 0.090 |
Why?
|
| Benzazepines | 1 | 2013 | 311 | 0.090 |
Why?
|
| Chronic Disease | 6 | 2006 | 9382 | 0.090 |
Why?
|
| Colorado | 2 | 2014 | 166 | 0.090 |
Why?
|
| Penicillin V | 1 | 1990 | 18 | 0.090 |
Why?
|
| Acute Disease | 4 | 2008 | 7246 | 0.090 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2012 | 325 | 0.090 |
Why?
|
| Stroke | 3 | 2022 | 9791 | 0.090 |
Why?
|
| Amides | 1 | 2013 | 452 | 0.090 |
Why?
|
| Equipment Contamination | 2 | 1989 | 183 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2009 | 8538 | 0.090 |
Why?
|
| Texas | 2 | 2010 | 405 | 0.090 |
Why?
|
| Hospitals, Urban | 2 | 2003 | 501 | 0.090 |
Why?
|
| Economics, Hospital | 1 | 2012 | 210 | 0.090 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 823 | 0.090 |
Why?
|
| Mothers | 1 | 2001 | 2210 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 2 | 2014 | 2489 | 0.090 |
Why?
|
| Lactic Acid | 1 | 2015 | 1140 | 0.090 |
Why?
|
| Gonorrhea | 3 | 2003 | 349 | 0.090 |
Why?
|
| Software Design | 1 | 2010 | 173 | 0.080 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2015 | 470 | 0.080 |
Why?
|
| Diagnostic Errors | 2 | 2007 | 1282 | 0.080 |
Why?
|
| Intensive Care Units, Neonatal | 6 | 2003 | 861 | 0.080 |
Why?
|
| Public Policy | 1 | 2014 | 560 | 0.080 |
Why?
|
| Interinstitutional Relations | 1 | 2011 | 236 | 0.080 |
Why?
|
| Methicillin | 2 | 2006 | 62 | 0.080 |
Why?
|
| Health Behavior | 1 | 2001 | 2649 | 0.080 |
Why?
|
| Proportional Hazards Models | 7 | 2020 | 12561 | 0.080 |
Why?
|
| Shigella | 1 | 2009 | 69 | 0.080 |
Why?
|
| Insurance Carriers | 1 | 2011 | 158 | 0.080 |
Why?
|
| Cost Savings | 1 | 2014 | 916 | 0.080 |
Why?
|
| HIV Protease Inhibitors | 2 | 2002 | 432 | 0.080 |
Why?
|
| Streptococcus pyogenes | 1 | 1991 | 293 | 0.080 |
Why?
|
| Dysentery, Bacillary | 1 | 2009 | 73 | 0.080 |
Why?
|
| HLA Antigens | 2 | 2014 | 1338 | 0.080 |
Why?
|
| Documentation | 1 | 2015 | 913 | 0.080 |
Why?
|
| Smoking | 3 | 2020 | 9099 | 0.080 |
Why?
|
| Consumer Product Safety | 1 | 2009 | 122 | 0.080 |
Why?
|
| Transducers, Pressure | 1 | 1988 | 51 | 0.080 |
Why?
|
| Health Facility Administrators | 1 | 2008 | 32 | 0.080 |
Why?
|
| Housekeeping, Hospital | 1 | 2008 | 17 | 0.080 |
Why?
|
| Trimethoprim | 1 | 1988 | 80 | 0.080 |
Why?
|
| Vaccines, Attenuated | 3 | 2015 | 315 | 0.080 |
Why?
|
| Diagnosis-Related Groups | 2 | 2003 | 448 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2000 | 1816 | 0.080 |
Why?
|
| Diuretics | 3 | 2021 | 612 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 6 | 2017 | 5532 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 2 | 2014 | 1509 | 0.080 |
Why?
|
| Anaphylaxis | 1 | 2015 | 758 | 0.080 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2008 | 142 | 0.080 |
Why?
|
| Prenatal Care | 2 | 2007 | 1159 | 0.080 |
Why?
|
| Urticaria | 1 | 2009 | 151 | 0.080 |
Why?
|
| Insulin | 2 | 2003 | 6606 | 0.080 |
Why?
|
| Health Services | 2 | 2004 | 756 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 4049 | 0.070 |
Why?
|
| Likelihood Functions | 3 | 2013 | 993 | 0.070 |
Why?
|
| Cefsulodin | 2 | 1984 | 5 | 0.070 |
Why?
|
| Nasal Cavity | 3 | 2014 | 309 | 0.070 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2008 | 123 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2016 | 1965 | 0.070 |
Why?
|
| Severity of Illness Index | 6 | 2015 | 15965 | 0.070 |
Why?
|
| Intestinal Diseases | 1 | 1992 | 505 | 0.070 |
Why?
|
| Infusions, Parenteral | 2 | 2001 | 398 | 0.070 |
Why?
|
| Administration, Oral | 4 | 2020 | 4041 | 0.070 |
Why?
|
| Birth Weight | 4 | 2001 | 2117 | 0.070 |
Why?
|
| Gemfibrozil | 1 | 2007 | 30 | 0.070 |
Why?
|
| Statistics as Topic | 3 | 2020 | 2362 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 1997 | 2170 | 0.070 |
Why?
|
| Naproxen | 1 | 2007 | 101 | 0.070 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1990 | 314 | 0.070 |
Why?
|
| Kidney Transplantation | 2 | 2014 | 4285 | 0.070 |
Why?
|
| Pregnancy Outcome | 4 | 2014 | 2959 | 0.070 |
Why?
|
| Health Care Sector | 1 | 2009 | 196 | 0.070 |
Why?
|
| Reimbursement, Incentive | 1 | 2012 | 548 | 0.070 |
Why?
|
| Biometry | 2 | 2020 | 565 | 0.070 |
Why?
|
| Accidental Falls | 1 | 1995 | 1081 | 0.070 |
Why?
|
| Urban Health | 1 | 2010 | 535 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 4 | 2013 | 7451 | 0.070 |
Why?
|
| Transducers | 1 | 1988 | 245 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2001 | 3682 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2014 | 1249 | 0.070 |
Why?
|
| Antioxidants | 1 | 2015 | 1678 | 0.070 |
Why?
|
| Aluminum | 1 | 2007 | 152 | 0.070 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2009 | 462 | 0.070 |
Why?
|
| Lactams | 2 | 2004 | 158 | 0.070 |
Why?
|
| Fenofibrate | 1 | 2007 | 87 | 0.070 |
Why?
|
| Specialization | 1 | 2011 | 782 | 0.070 |
Why?
|
| Infection Control Practitioners | 1 | 2006 | 12 | 0.070 |
Why?
|
| Pharmacology, Clinical | 1 | 2006 | 23 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 2291 | 0.070 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2013 | 1066 | 0.070 |
Why?
|
| Delivery, Obstetric | 2 | 2005 | 953 | 0.070 |
Why?
|
| Amitriptyline | 1 | 2006 | 112 | 0.060 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 1998 | 238 | 0.060 |
Why?
|
| Hypertension | 2 | 2009 | 8611 | 0.060 |
Why?
|
| Recurrence | 4 | 2011 | 8510 | 0.060 |
Why?
|
| Graft Survival | 2 | 2014 | 3890 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2003 | 1585 | 0.060 |
Why?
|
| Decision Theory | 1 | 2005 | 27 | 0.060 |
Why?
|
| Pandemics | 4 | 2024 | 8753 | 0.060 |
Why?
|
| Cephamycins | 2 | 1982 | 6 | 0.060 |
Why?
|
| New England | 3 | 2002 | 1056 | 0.060 |
Why?
|
| Protective Clothing | 1 | 2005 | 103 | 0.060 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 1262 | 0.060 |
Why?
|
| Gynecology | 1 | 2011 | 532 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2008 | 3484 | 0.060 |
Why?
|
| Torsades de Pointes | 1 | 2006 | 78 | 0.060 |
Why?
|
| Premature Birth | 2 | 2015 | 1816 | 0.060 |
Why?
|
| Lactones | 1 | 2007 | 316 | 0.060 |
Why?
|
| Blood Transfusion | 1 | 2012 | 1308 | 0.060 |
Why?
|
| Health Resources | 2 | 2003 | 950 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1995 | 2258 | 0.060 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2005 | 52 | 0.060 |
Why?
|
| Episode of Care | 2 | 2005 | 128 | 0.060 |
Why?
|
| Deductibles and Coinsurance | 1 | 2007 | 316 | 0.060 |
Why?
|
| Bacillus anthracis | 1 | 2005 | 120 | 0.060 |
Why?
|
| Sulfones | 1 | 2007 | 448 | 0.060 |
Why?
|
| Spores, Bacterial | 1 | 2005 | 114 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2002 | 5510 | 0.060 |
Why?
|
| Geography | 2 | 2009 | 654 | 0.060 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2005 | 146 | 0.060 |
Why?
|
| Indinavir | 2 | 2002 | 73 | 0.060 |
Why?
|
| Postoperative Complications | 6 | 2001 | 15880 | 0.060 |
Why?
|
| Mammaplasty | 2 | 2004 | 1262 | 0.060 |
Why?
|
| Penicillin Resistance | 1 | 2004 | 77 | 0.060 |
Why?
|
| Prescription Fees | 1 | 2005 | 153 | 0.060 |
Why?
|
| Self Administration | 1 | 2005 | 387 | 0.060 |
Why?
|
| Analysis of Variance | 4 | 2003 | 6242 | 0.060 |
Why?
|
| Censuses | 1 | 2005 | 198 | 0.060 |
Why?
|
| Medical Record Linkage | 3 | 2012 | 286 | 0.060 |
Why?
|
| Concurrent Review | 1 | 2003 | 13 | 0.060 |
Why?
|
| Republic of Belarus | 3 | 2009 | 38 | 0.060 |
Why?
|
| Quality Control | 1 | 2007 | 835 | 0.060 |
Why?
|
| Cholinergic Antagonists | 1 | 2024 | 167 | 0.060 |
Why?
|
| Public Sector | 1 | 2005 | 265 | 0.060 |
Why?
|
| Surgery Department, Hospital | 1 | 2005 | 176 | 0.060 |
Why?
|
| Hip Fractures | 2 | 2003 | 996 | 0.050 |
Why?
|
| Vaccines, Inactivated | 2 | 2015 | 185 | 0.050 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2003 | 86 | 0.050 |
Why?
|
| Focal Infection | 1 | 1982 | 9 | 0.050 |
Why?
|
| Infant Food | 1 | 2003 | 139 | 0.050 |
Why?
|
| Peritoneal Dialysis | 1 | 1984 | 160 | 0.050 |
Why?
|
| Socioeconomic Factors | 4 | 2009 | 7863 | 0.050 |
Why?
|
| Program Evaluation | 2 | 2012 | 2508 | 0.050 |
Why?
|
| Glycopeptides | 1 | 2004 | 220 | 0.050 |
Why?
|
| Fetal Growth Retardation | 2 | 2015 | 585 | 0.050 |
Why?
|
| Reference Values | 2 | 2008 | 4941 | 0.050 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2004 | 272 | 0.050 |
Why?
|
| Biological Products | 1 | 2012 | 937 | 0.050 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2008 | 454 | 0.050 |
Why?
|
| Private Sector | 1 | 2005 | 395 | 0.050 |
Why?
|
| Calcitonin | 1 | 2003 | 329 | 0.050 |
Why?
|
| United States Dept. of Health and Human Services | 2 | 2012 | 88 | 0.050 |
Why?
|
| Neisseria gonorrhoeae | 2 | 2001 | 243 | 0.050 |
Why?
|
| Antipsychotic Agents | 2 | 2024 | 3077 | 0.050 |
Why?
|
| Peritonitis | 1 | 1984 | 368 | 0.050 |
Why?
|
| Serotyping | 3 | 2012 | 332 | 0.050 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2006 | 775 | 0.050 |
Why?
|
| Cost Sharing | 1 | 2005 | 409 | 0.050 |
Why?
|
| Education, Medical | 1 | 2013 | 1742 | 0.050 |
Why?
|
| Conjunctivitis | 1 | 2003 | 156 | 0.050 |
Why?
|
| Wrist Injuries | 2 | 2003 | 215 | 0.050 |
Why?
|
| Electrocardiography | 1 | 1995 | 6410 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2009 | 2733 | 0.050 |
Why?
|
| Liver Function Tests | 1 | 2003 | 527 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2024 | 622 | 0.050 |
Why?
|
| Viral Hepatitis Vaccines | 3 | 1986 | 72 | 0.050 |
Why?
|
| Central Nervous System Stimulants | 1 | 2010 | 1180 | 0.050 |
Why?
|
| Diabetes, Gestational | 1 | 2011 | 1259 | 0.050 |
Why?
|
| Urethritis | 1 | 2001 | 24 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2011 | 1926 | 0.050 |
Why?
|
| Hospitals, University | 2 | 2014 | 569 | 0.050 |
Why?
|
| Chlamydia Infections | 2 | 2003 | 365 | 0.050 |
Why?
|
| Meningitis | 1 | 2003 | 219 | 0.050 |
Why?
|
| Paronychia | 1 | 2001 | 10 | 0.050 |
Why?
|
| Smoking Cessation | 1 | 2013 | 2079 | 0.050 |
Why?
|
| Cisapride | 1 | 2000 | 22 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2024 | 319 | 0.050 |
Why?
|
| Cost of Illness | 2 | 2003 | 1960 | 0.050 |
Why?
|
| Developed Countries | 1 | 2004 | 451 | 0.050 |
Why?
|
| Splenectomy | 1 | 1982 | 392 | 0.050 |
Why?
|
| Economics, Pharmaceutical | 1 | 2001 | 88 | 0.050 |
Why?
|
| Bronchitis | 1 | 2001 | 196 | 0.050 |
Why?
|
| User-Computer Interface | 1 | 2007 | 1397 | 0.050 |
Why?
|
| Cromolyn Sodium | 2 | 2000 | 78 | 0.050 |
Why?
|
| Liver Failure | 1 | 2003 | 252 | 0.050 |
Why?
|
| Penicillins | 1 | 2004 | 405 | 0.050 |
Why?
|
| Washington | 1 | 2001 | 314 | 0.040 |
Why?
|
| Mycoplasma Infections | 1 | 1980 | 120 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2014 | 4505 | 0.040 |
Why?
|
| Ultraviolet Rays | 1 | 2005 | 1100 | 0.040 |
Why?
|
| Staphylococcus | 3 | 1990 | 153 | 0.040 |
Why?
|
| Muscular Diseases | 1 | 2005 | 555 | 0.040 |
Why?
|
| Phylogeny | 1 | 2008 | 2846 | 0.040 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2003 | 399 | 0.040 |
Why?
|
| Medication Errors | 1 | 2006 | 783 | 0.040 |
Why?
|
| Fetus | 1 | 2007 | 1883 | 0.040 |
Why?
|
| Otitis Media | 2 | 1994 | 288 | 0.040 |
Why?
|
| Caregivers | 2 | 2024 | 2302 | 0.040 |
Why?
|
| Half-Life | 1 | 2000 | 650 | 0.040 |
Why?
|
| Hypersensitivity | 1 | 2009 | 1172 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2005 | 937 | 0.040 |
Why?
|
| Community Networks | 1 | 2001 | 202 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2008 | 1197 | 0.040 |
Why?
|
| Moxalactam | 3 | 1984 | 9 | 0.040 |
Why?
|
| Chlamydia trachomatis | 1 | 2001 | 239 | 0.040 |
Why?
|
| Protective Agents | 1 | 2000 | 151 | 0.040 |
Why?
|
| Blood Proteins | 1 | 1984 | 1183 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2011 | 1948 | 0.040 |
Why?
|
| Demography | 1 | 2004 | 1643 | 0.040 |
Why?
|
| Pharmacy | 1 | 2021 | 92 | 0.040 |
Why?
|
| Parturition | 1 | 2003 | 453 | 0.040 |
Why?
|
| Adamantane | 1 | 2020 | 148 | 0.040 |
Why?
|
| Survival Rate | 2 | 2014 | 12875 | 0.040 |
Why?
|
| Double-Blind Method | 5 | 2021 | 12450 | 0.040 |
Why?
|
| Diphosphonates | 1 | 2003 | 635 | 0.040 |
Why?
|
| Erectile Dysfunction | 1 | 2002 | 445 | 0.040 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1998 | 113 | 0.040 |
Why?
|
| Legislation, Drug | 1 | 2000 | 216 | 0.040 |
Why?
|
| Endocarditis, Bacterial | 1 | 1982 | 438 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2005 | 2437 | 0.040 |
Why?
|
| Dipeptides | 1 | 2020 | 386 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2007 | 1988 | 0.040 |
Why?
|
| Administration, Inhalation | 2 | 2000 | 1170 | 0.040 |
Why?
|
| Pregnancy, Multiple | 1 | 1998 | 216 | 0.040 |
Why?
|
| Cough | 1 | 2001 | 598 | 0.040 |
Why?
|
| Warfarin | 1 | 2006 | 1493 | 0.040 |
Why?
|
| Reference Standards | 1 | 2021 | 1015 | 0.040 |
Why?
|
| Spinal Fractures | 2 | 2003 | 712 | 0.040 |
Why?
|
| Pharmacogenetics | 1 | 2001 | 677 | 0.040 |
Why?
|
| Humeral Fractures | 1 | 2000 | 283 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2007 | 2024 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2011 | 26351 | 0.030 |
Why?
|
| Mental Health | 1 | 2011 | 3271 | 0.030 |
Why?
|
| Tibial Fractures | 1 | 2000 | 276 | 0.030 |
Why?
|
| Theophylline | 1 | 1997 | 133 | 0.030 |
Why?
|
| Fasciitis, Necrotizing | 1 | 1997 | 79 | 0.030 |
Why?
|
| Twins | 1 | 1998 | 340 | 0.030 |
Why?
|
| Myocardial Infarction | 2 | 2008 | 11515 | 0.030 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 1188 | 0.030 |
Why?
|
| Dermatitis, Atopic | 1 | 2004 | 734 | 0.030 |
Why?
|
| Patient Admission | 2 | 2003 | 1370 | 0.030 |
Why?
|
| Seasons | 3 | 2005 | 1526 | 0.030 |
Why?
|
| Observation | 2 | 2009 | 311 | 0.030 |
Why?
|
| Acyclovir | 1 | 1997 | 267 | 0.030 |
Why?
|
| Depression | 1 | 1996 | 8235 | 0.030 |
Why?
|
| Monitoring, Ambulatory | 1 | 1999 | 357 | 0.030 |
Why?
|
| Hospital Mortality | 2 | 2015 | 5371 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2000 | 510 | 0.030 |
Why?
|
| Steroids | 2 | 2000 | 937 | 0.030 |
Why?
|
| Sampling Studies | 1 | 1997 | 617 | 0.030 |
Why?
|
| Patellar Ligament | 1 | 2016 | 66 | 0.030 |
Why?
|
| Coagulase | 3 | 1990 | 53 | 0.030 |
Why?
|
| Israel | 1 | 1998 | 726 | 0.030 |
Why?
|
| Methods | 1 | 1996 | 1067 | 0.030 |
Why?
|
| Age of Onset | 1 | 2003 | 3342 | 0.030 |
Why?
|
| Pyridines | 1 | 2007 | 2888 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2003 | 1076 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1997 | 347 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 13589 | 0.030 |
Why?
|
| Northwestern United States | 1 | 2014 | 20 | 0.030 |
Why?
|
| Erythromycin | 1 | 1995 | 115 | 0.030 |
Why?
|
| Urban Population | 1 | 2003 | 2047 | 0.030 |
Why?
|
| Universities | 1 | 2020 | 1007 | 0.030 |
Why?
|
| Candida | 1 | 2015 | 172 | 0.030 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 3742 | 0.030 |
Why?
|
| Propranolol | 1 | 1996 | 493 | 0.030 |
Why?
|
| Ohio | 1 | 2015 | 328 | 0.030 |
Why?
|
| Infant, Premature, Diseases | 1 | 2000 | 712 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 14766 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 857 | 0.030 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2000 | 592 | 0.030 |
Why?
|
| Suburethral Slings | 1 | 2015 | 72 | 0.030 |
Why?
|
| Research Report | 1 | 2017 | 369 | 0.030 |
Why?
|
| Current Procedural Terminology | 1 | 2015 | 101 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2016 | 707 | 0.030 |
Why?
|
| Infant, Premature | 2 | 2001 | 2124 | 0.030 |
Why?
|
| Laminectomy | 1 | 2015 | 226 | 0.030 |
Why?
|
| HIV-1 | 2 | 2002 | 6966 | 0.030 |
Why?
|
| Pulmonary Atelectasis | 1 | 2015 | 160 | 0.030 |
Why?
|
| Emergencies | 1 | 2000 | 1222 | 0.030 |
Why?
|
| Physician's Role | 1 | 2000 | 927 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2000 | 1296 | 0.030 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2004 | 1931 | 0.030 |
Why?
|
| Immunization, Secondary | 2 | 2014 | 371 | 0.030 |
Why?
|
| Postoperative Period | 1 | 1998 | 1833 | 0.030 |
Why?
|
| Educational Status | 1 | 2000 | 2519 | 0.030 |
Why?
|
| Prospective Payment System | 1 | 2013 | 136 | 0.030 |
Why?
|
| Birth Certificates | 1 | 2012 | 71 | 0.030 |
Why?
|
| Occupational Diseases | 3 | 1986 | 1494 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 1994 | 557 | 0.030 |
Why?
|
| Genes, Bacterial | 1 | 2016 | 1076 | 0.030 |
Why?
|
| Cholecystectomy | 1 | 2015 | 409 | 0.030 |
Why?
|
| Fetal Death | 1 | 2014 | 438 | 0.030 |
Why?
|
| Morbidity | 2 | 2000 | 1760 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 1408 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2007 | 2444 | 0.030 |
Why?
|
| Oxygen | 1 | 2024 | 4269 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 4 | 1986 | 294 | 0.020 |
Why?
|
| Syncope | 1 | 1995 | 430 | 0.020 |
Why?
|
| Reoperation | 2 | 2014 | 4342 | 0.020 |
Why?
|
| Antidiarrheals | 1 | 2012 | 46 | 0.020 |
Why?
|
| Foodborne Diseases | 1 | 2012 | 41 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 2015 | 409 | 0.020 |
Why?
|
| Cryptosporidium | 1 | 2012 | 43 | 0.020 |
Why?
|
| Income | 1 | 2000 | 1878 | 0.020 |
Why?
|
| Enterotoxins | 1 | 2013 | 366 | 0.020 |
Why?
|
| Meningitis, Bacterial | 1 | 1994 | 225 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 2016 | 877 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 1997 | 867 | 0.020 |
Why?
|
| Salmonella | 1 | 2012 | 125 | 0.020 |
Why?
|
| Drug Contamination | 2 | 1990 | 152 | 0.020 |
Why?
|
| Hospital Charges | 2 | 2003 | 351 | 0.020 |
Why?
|
| Bone Transplantation | 1 | 2016 | 925 | 0.020 |
Why?
|
| Appendectomy | 1 | 2015 | 442 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 3816 | 0.020 |
Why?
|
| Comprehensive Health Care | 1 | 2012 | 123 | 0.020 |
Why?
|
| Markov Chains | 1 | 2015 | 977 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2012 | 5308 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2015 | 797 | 0.020 |
Why?
|
| Hepatitis B Antibodies | 3 | 1986 | 155 | 0.020 |
Why?
|
| Government Regulation | 1 | 2015 | 525 | 0.020 |
Why?
|
| Models, Economic | 1 | 2015 | 717 | 0.020 |
Why?
|
| Arthritis, Infectious | 1 | 1994 | 347 | 0.020 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 595 | 0.020 |
Why?
|
| ROC Curve | 1 | 1998 | 3624 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 1999 | 2396 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 1993 | 335 | 0.020 |
Why?
|
| Clinical Audit | 1 | 2009 | 29 | 0.020 |
Why?
|
| Osteomyelitis | 1 | 1994 | 408 | 0.020 |
Why?
|
| Group Practice | 1 | 2010 | 151 | 0.020 |
Why?
|
| Ethanol | 2 | 1988 | 1334 | 0.020 |
Why?
|
| Waiting Lists | 1 | 2014 | 778 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 13065 | 0.020 |
Why?
|
| Pacemaker, Artificial | 1 | 2015 | 828 | 0.020 |
Why?
|
| Argentina | 1 | 2009 | 248 | 0.020 |
Why?
|
| Risk Adjustment | 1 | 2012 | 603 | 0.020 |
Why?
|
| Ethylene Oxide | 1 | 1988 | 28 | 0.020 |
Why?
|
| Linear Models | 2 | 2012 | 5880 | 0.020 |
Why?
|
| Shock, Septic | 1 | 2015 | 774 | 0.020 |
Why?
|
| Pharyngitis | 1 | 1990 | 222 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 1629 | 0.020 |
Why?
|
| Regenerative Medicine | 1 | 2012 | 311 | 0.020 |
Why?
|
| Environmental Microbiology | 1 | 2008 | 47 | 0.020 |
Why?
|
| HIV Infections | 3 | 2002 | 17564 | 0.020 |
Why?
|
| Necrosis | 1 | 1992 | 1621 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2019 | 3115 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2013 | 926 | 0.020 |
Why?
|
| Postal Service | 1 | 2008 | 96 | 0.020 |
Why?
|
| Sterilization | 1 | 1988 | 132 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 1994 | 3438 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2011 | 633 | 0.020 |
Why?
|
| Tobacco Use Disorder | 1 | 2013 | 710 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 1988 | 161 | 0.020 |
Why?
|
| Bone Density | 1 | 2000 | 3561 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2007 | 286 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 6091 | 0.020 |
Why?
|
| Diagnosis | 1 | 1988 | 156 | 0.020 |
Why?
|
| Death, Sudden, Cardiac | 1 | 1995 | 1568 | 0.020 |
Why?
|
| Leukotriene Antagonists | 1 | 2007 | 124 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 10784 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 2008 | 313 | 0.020 |
Why?
|
| Cause of Death | 2 | 2011 | 3727 | 0.020 |
Why?
|
| Doxycycline | 1 | 2008 | 348 | 0.020 |
Why?
|
| Obstetric Labor, Premature | 1 | 2007 | 273 | 0.020 |
Why?
|
| Financing, Government | 1 | 2009 | 473 | 0.020 |
Why?
|
| Deltaretrovirus | 1 | 1985 | 162 | 0.020 |
Why?
|
| Fluconazole | 1 | 2006 | 156 | 0.020 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2007 | 433 | 0.020 |
Why?
|
| Tissue and Organ Procurement | 1 | 2014 | 983 | 0.020 |
Why?
|
| Online Systems | 1 | 2006 | 182 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2014 | 4834 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 4780 | 0.020 |
Why?
|
| Cephradine | 1 | 1984 | 4 | 0.020 |
Why?
|
| Feces | 1 | 2012 | 1515 | 0.020 |
Why?
|
| Coronary Disease | 1 | 1999 | 5926 | 0.020 |
Why?
|
| Nafcillin | 1 | 1984 | 23 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3246 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 1995 | 2666 | 0.010 |
Why?
|
| Metronidazole | 1 | 2006 | 233 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 1990 | 961 | 0.010 |
Why?
|
| Skin Diseases | 1 | 1993 | 1099 | 0.010 |
Why?
|
| Hepatitis B Vaccines | 4 | 1986 | 177 | 0.010 |
Why?
|
| Hospital Administration | 1 | 1988 | 353 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2014 | 2377 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 1990 | 1276 | 0.010 |
Why?
|
| Urine | 2 | 1982 | 363 | 0.010 |
Why?
|
| Prognosis | 2 | 2014 | 30028 | 0.010 |
Why?
|
| Pyelonephritis | 1 | 1983 | 76 | 0.010 |
Why?
|
| Heart Rate | 1 | 1995 | 4218 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2003 | 7956 | 0.010 |
Why?
|
| Rectal Diseases | 1 | 1984 | 142 | 0.010 |
Why?
|
| Genital Diseases, Female | 1 | 1984 | 193 | 0.010 |
Why?
|
| Hospitals, General | 1 | 1988 | 807 | 0.010 |
Why?
|
| APACHE | 1 | 2003 | 268 | 0.010 |
Why?
|
| Ticarcillin | 1 | 1982 | 8 | 0.010 |
Why?
|
| Cefoperazone | 1 | 1982 | 7 | 0.010 |
Why?
|
| Financing, Personal | 1 | 2005 | 310 | 0.010 |
Why?
|
| Catheterization | 1 | 1988 | 1431 | 0.010 |
Why?
|
| Chromans | 1 | 2003 | 117 | 0.010 |
Why?
|
| Colonic Diseases | 1 | 1984 | 203 | 0.010 |
Why?
|
| Delirium | 1 | 2015 | 1694 | 0.010 |
Why?
|
| Ceftazidime | 1 | 1982 | 57 | 0.010 |
Why?
|
| Saquinavir | 1 | 2002 | 29 | 0.010 |
Why?
|
| Tobramycin | 1 | 1982 | 65 | 0.010 |
Why?
|
| Neoplasms | 1 | 2011 | 22386 | 0.010 |
Why?
|
| Nelfinavir | 1 | 2002 | 68 | 0.010 |
Why?
|
| Disease | 1 | 1988 | 673 | 0.010 |
Why?
|
| Bacteria | 2 | 1983 | 2226 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1988 | 2079 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1984 | 621 | 0.010 |
Why?
|
| Acetaminophen | 1 | 2006 | 556 | 0.010 |
Why?
|
| Mastectomy | 1 | 1990 | 1852 | 0.010 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2001 | 29 | 0.010 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1983 | 190 | 0.010 |
Why?
|
| Sulfonylurea Compounds | 1 | 2003 | 220 | 0.010 |
Why?
|
| Ureaplasma | 1 | 1980 | 60 | 0.010 |
Why?
|
| Quality of Life | 1 | 2003 | 13497 | 0.010 |
Why?
|
| Expert Systems | 1 | 2001 | 79 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1982 | 1310 | 0.010 |
Why?
|
| Mycoplasma | 1 | 1980 | 147 | 0.010 |
Why?
|
| Hepatitis B virus | 1 | 1984 | 530 | 0.010 |
Why?
|
| Mass Screening | 2 | 2014 | 5455 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1984 | 1604 | 0.010 |
Why?
|
| Ritonavir | 1 | 2002 | 330 | 0.010 |
Why?
|
| Immunization | 1 | 1984 | 1220 | 0.010 |
Why?
|
| Uric Acid | 1 | 2006 | 807 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1984 | 2488 | 0.010 |
Why?
|
| Respiratory Sounds | 1 | 2004 | 702 | 0.010 |
Why?
|
| Birth Rate | 1 | 2001 | 168 | 0.010 |
Why?
|
| Nursing Homes | 1 | 1987 | 1084 | 0.010 |
Why?
|
| Blood Coagulation Disorders | 1 | 1982 | 350 | 0.010 |
Why?
|
| Abscess | 1 | 1983 | 607 | 0.010 |
Why?
|
| Polymyxins | 1 | 1978 | 17 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 1984 | 596 | 0.010 |
Why?
|
| Neomycin | 1 | 1978 | 94 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1983 | 709 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1984 | 1532 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 1891 | 0.010 |
Why?
|
| Twins, Dizygotic | 1 | 1998 | 236 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1982 | 1339 | 0.010 |
Why?
|
| Therapeutic Irrigation | 1 | 1978 | 297 | 0.010 |
Why?
|
| Bronchodilator Agents | 1 | 2000 | 519 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 1983 | 1160 | 0.010 |
Why?
|
| Twins, Monozygotic | 1 | 1998 | 472 | 0.010 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1984 | 1277 | 0.010 |
Why?
|
| Spleen | 1 | 1982 | 2298 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2007 | 2102 | 0.010 |
Why?
|
| Animals | 3 | 2015 | 169418 | 0.010 |
Why?
|
| Orthopedics | 1 | 1984 | 906 | 0.010 |
Why?
|
| Thiazoles | 1 | 2003 | 1541 | 0.010 |
Why?
|
| Metformin | 1 | 2003 | 914 | 0.010 |
Why?
|
| Vagina | 1 | 1980 | 845 | 0.010 |
Why?
|
| Insurance Coverage | 1 | 2006 | 1946 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2001 | 2596 | 0.010 |
Why?
|
| Causality | 1 | 2001 | 1255 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 2 | 1990 | 875 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1985 | 3212 | 0.010 |
Why?
|
| Protein Binding | 1 | 1984 | 9376 | 0.010 |
Why?
|
| Pain | 2 | 1984 | 5096 | 0.010 |
Why?
|
| Tennessee | 1 | 1991 | 123 | 0.010 |
Why?
|
| Myocardium | 1 | 1984 | 4788 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 16712 | 0.010 |
Why?
|
| Neutrophils | 1 | 1984 | 3790 | 0.010 |
Why?
|
| Viral Load | 1 | 2001 | 3399 | 0.010 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1993 | 664 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1993 | 963 | 0.000 |
Why?
|
| Haploidy | 1 | 1986 | 127 | 0.000 |
Why?
|
| Survival Analysis | 1 | 1998 | 10125 | 0.000 |
Why?
|
| Chemical Precipitation | 1 | 1985 | 175 | 0.000 |
Why?
|
| Hepatitis B Core Antigens | 1 | 1985 | 90 | 0.000 |
Why?
|
| Immunization Schedule | 1 | 1986 | 227 | 0.000 |
Why?
|
| HLA-DR Antigens | 1 | 1986 | 607 | 0.000 |
Why?
|
| Antibody Specificity | 1 | 1985 | 1065 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1986 | 739 | 0.000 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1986 | 1438 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1985 | 2477 | 0.000 |
Why?
|
| Immunologic Memory | 1 | 1985 | 1375 | 0.000 |
Why?
|
| Hospitals, Pediatric | 1 | 1987 | 1876 | 0.000 |
Why?
|
| Enterococcus faecalis | 1 | 1978 | 245 | 0.000 |
Why?
|
| Candida albicans | 1 | 1978 | 376 | 0.000 |
Why?
|